Portfolio of Big Pharma and Biotech Cancer Immunotherapy Stocks
Here are 10 big pharma and big biotech cancer immunotherapy stocks.
| 10 Big Pharma and Biotech Cancer Immunotherapy Stocks | ||
|---|---|---|
Stock Returns & Price Chart | Symbol | Recent Prices & |
| Amgen | AMGN | |
| AstraZeneca | AZN | |
| Bristol-Myers Squibb | BMY | |
| Celgene | CELG | |
| Gilead Sciences | GILD | |
| Incyte Corporation | INCY | |
| Merck | MRK | |
| Nektar Therapeutics | NKTR | |
| Novartis | NVS | |
| Pfizer | PFE | |
| Price data from Quandl as of most recent close. | ||
To inspect the performance of the Big Pharma and Biotech Cancer Immunotherapy Stocks portfolio, see the chart below. Portfolio values are computed using monthly closes for stocks from Quandl.All 10 stocks are included in the portfolio computations. The current value of the portfolio assumes that $1,000.00 was invested (total of $10,000) in each stock at its closing monthly price for the first date shown on the portfolio value chart below. All prices are adjusted for splits and dividends.
The current value of a $10,000 investment is $41,248. The percent return is 312.48%. The annualized return is 15.22%.
| Return Summary for Big Pharma and Biotech Cancer Immunotherapy Stocks | |
|---|---|
| Start Date | Aug-31-2009 |
| Start Investment | $10,000.00 |
| End Date | Aug-23-2019 |
| Current Value of Investment | $41,248.25 |
| Total Return | 312.48% |
| Annualized Return | 15.22% |
| Min Date | Oct-30-2009 |
| Min Price | $9,758.35 |
| Max Date | Mar-29-2018 |
| Max Price | $49,669.29 |
| # Values | 121 |
| Number Returns | 7,260 |
| Number Profitable Returns | 6,497 |
| Percent Profitable Returns | 89.49% |
| Number Unprofitable Returns | 763 |
| Percent Unprofitable Returns | 10.51% |
| Profitable to Unprofitable Returns Ratio | 8.52 |
NOTE: The stocks included in the tables and chart are representative of the industry. They are not recommendations.